Story perspectives

ELI-002 Vaccine Trial Advances, Stock Soars on Safety Data

8/19/2025

48 4

Center

Elicio Advances Cancer Vaccine

Elicio Therapeutics is conducting a phase II trial, AMPLIFY-7P, for its ELI-002 vaccine in 135 pancreatic cancer patients.
An Independent Data Monitoring Committee confirmed ELI-002's safety profile, allowing the trial to continue unchanged.
The final analysis on disease-free survival is expected in Q4 2025, with an FDA meeting planned for Phase 3 discussion.
Updated phase I data indicates a median relapse-free survival of 16.33 months and overall survival of 28.94 months in a 25-patient cohort.
Elicio's stock has increased significantly since its Nasdaq debut, reflecting strong investor interest.

Right

ELI-002 Vaccine Success

The ELI-002 2P cancer vaccine shows potential in preventing pancreatic and colorectal cancer recurrence, based on a UCLA-led phase 1 trial with 25 patients.
Over 80% of participants exhibited strong immune responses, with some cancer-free for nearly 20 months.
The vaccine targets KRAS mutations and is mass-produced to enhance anti-tumor activity.
A phase 2 study is planned to further evaluate its effectiveness.

1 of 2

Elicio Advances Cancer Vaccine

Elicio Therapeutics is conducting a phase II trial, AMPLIFY-7P, for its ELI-002 vaccine in 135 pancreatic cancer patients.
An Independent Data Monitoring Committee confirmed ELI-002's safety profile, allowing the trial to continue unchanged.
The final analysis on disease-free survival is expected in Q4 2025, with an FDA meeting planned for Phase 3 discussion.
Updated phase I data indicates a median relapse-free survival of 16.33 months and overall survival of 28.94 months in a 25-patient cohort.
Elicio's stock has increased significantly since its Nasdaq debut, reflecting strong investor interest.

1 / 2